A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Use of Novel Anti-inflammatory Agents to Inhibit Osteosarcoma Lung Metastasis
Currently the 5-year survival rate for osteosarcoma patients with pulmonary metastasis is less than 30%, identifying a need for novel approaches to inhibit metastasis. Consistent with an emerging understanding of the cancer-inflammation relationship, a requirement for neutrophils in metastasis was recently proposed. Here we assessed the potential requisite of neutrophils and the effects of two novel anti-inflammatory agents in osteosarcoma metastasis: LT-peptide and GML (GM1-Targeteddoi:10.11575/prism/28609 fatcat:uzwlaw243zh5nnmk6vmasosxzm